The company's financial stability appears fragile, as evidenced by an accumulated deficit of $9.5M and a shrinking asset base that declined from $4.9M in 2023Q4 to $3.9M in 2026Q1.
| Total Current Assets | 3.93M | 2.74M | 3.35M | 4.78M | 1.43M | 382.14K | 3K |
| Cash & Short-Term Investments | 2.92M | 1.61M | 2.4M | 3.28M | 3.34K | 100.01K | 3K |
| Cash Only | 2.92M | 1.61M | 2.4M | 3.28M | 3.34K | 100.01K | 3K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 869.13K | 918.37K | 680.83K | 1.18M | 1.35M | 282.13K | 0 |
| Days Sales Outstanding | 42.99 | 46.39 | 31.13 | 78.38 | 87.47 | 73.04 | - |
| Inventory | 0 | 0 | 0 | 0 | 47.21K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | 3.78 | - | - |
| Other Current Assets | 136.08K | 205.42K | 276.56K | 0 | -17.21K | 0 | 0 |
| Total Non-Current Assets | 16.99K | 34.39K | 325.54K | 142.17K | 892.9K | 154.75K | 0 |
| Property, Plant & Equipment | 16.99K | 34.39K | 325.54K | 142.17K | 296.78K | 154.75K | 0 |
| Fixed Asset Turnover | 217.19x | 210.14x | 24.52x | 38.79x | 18.93x | 9.11x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 596.12K | 0 | 0 |
| Total Assets | 3.94M | 2.77M | 3.68M | 4.92M | 2.32M | 536.89K | 3K |
| Asset Turnover | 2.27x | 2.61x | 2.17x | 1.12x | 2.42x | 2.63x | - |
| Asset Growth % | -37.73% | -24.64% | -25.27% | 112.24% | 332.05% | 17796.3% | - |
| Total Current Liabilities | 1.58M | 674.74K | 613.55K | 910.07K | 1.55M | 452.29K | 7.17K |
| Accounts Payable | 464.92K | 319.52K | 101.69K | 462.99K | 435.59K | 125.73K | 0 |
| Days Payables Outstanding | 29.65 | 24.61 | 5.86 | 41.15 | 34.9 | 46.85 | - |
| Short-Term Debt | 73.09K | 143.79K | 152.89K | 184.9K | 750.55K | 194.2K | 3K |
| Deferred Revenue (Current) | 1.18M | 16.61K | 16.61K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 293.49K | 194.82K | 0 | 50.05K | 7.68K | -194.2K | -3K |
| Current Ratio | 2.48x | 4.06x | 5.46x | 5.25x | 0.92x | 0.84x | 0.42x |
| Quick Ratio | 2.48x | 4.06x | 5.46x | 5.25x | 0.89x | 0.84x | 0.42x |
| Cash Conversion Cycle | 13.34 | - | - | - | 56.35 | - | - |
| Total Non-Current Liabilities | 0 | 0 | 187.21K | 0 | 63.2K | 91.74K | 0 |
| Long-Term Debt | 0 | 0 | 187.21K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 63.2K | 91.74K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.58M | 674.74K | 800.76K | 910.07K | 1.61M | 544.04K | 7.17K |
| Total Debt | 73.09K | 143.79K | 452.08K | 248.1K | 934.84K | 342.86K | 3K |
| Net Debt | -2.85M | -1.47M | -1.94M | -3.03M | 931.5K | 242.85K | 0 |
| Debt / Equity | 0.03x | 0.07x | 0.16x | 0.06x | 1.32x | - | - |
| Debt / EBITDA | -0.32x | - | - | - | - | - | - |
| Net Debt / EBITDA | 12.57x | - | - | - | - | - | - |
| Interest Coverage | -18.42x | -68.15x | -239.98x | -53.73x | -73.24x | - | - |
| Total Equity | 2.36M | 2.1M | 2.88M | 4.01M | 710.1K | -7.15K | -4.17K |
| Equity Growth % | -49.22% | -27.11% | -28.27% | 465.16% | 10035.61% | -71.51% | - |
| Book Value per Share | 0.18 | 0.18 | 0.40 | 0.82 | 0.10 | -0.00 | -0.00 |
| Total Shareholders' Equity | 2.36M | 2.1M | 2.88M | 4.01M | 710.1K | -7.15K | -4.17K |
| Common Stock | 12.54K | 12.54K | 9.81K | 6.42K | 4.4K | 1K | 1K |
| Retained Earnings | -9.48M | -9.72M | -8.82M | -5.06M | -2.13M | -8.45K | -5.17K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital exhaustion and dilution
According to recent financial filings, SYRA's total assets have contracted from $4.9M in 2023Q4 to $3.9M in 2026Q1, reflecting a shrinking resource base that appears to struggle with maintaining operational scale while simultaneously attempting to fund a pivot toward digital health services.
The consistent decline in total assets suggests that the company is consuming its capital base to fund ongoing operating losses rather than reinvesting in growth-generating assets. This trajectory warrants concern, as the reduction in asset volume limits the company's ability to absorb future operational shocks or fund necessary R&D.
Based on reported figures, SYRA's cash position has fluctuated significantly, reaching a low of $1.6M in 2025Q4, which provides a precarious buffer against the company's persistent negative net margins and ongoing corporate overhead requirements.
While the current ratio of 2.48 suggests a superficial level of liquidity, the reliance on volatile government contract receivables makes this metric potentially misleading. Investors should monitor the cash runway closely, as the current burn rate may necessitate dilutive financing to maintain operations in the near term.
As reported in financial statements, SYRA's accumulated deficit has deepened to -$9.5M as of 2026Q1, illustrating a consistent erosion of shareholder equity that underscores the company's inability to achieve a self-sustaining business model since its inception.
The persistent negative retained earnings indicate that the company has yet to find a profitable equilibrium between its staffing and digital health segments. This trend suggests that equity value is being systematically depleted, placing the burden of future growth entirely on external capital raises.
Analysis of the balance sheet reveals that deferred revenue has swung from $0 in 2023Q4 to $750.5K in 2026Q1, a trend that may artificially inflate short-term liquidity metrics while obscuring the underlying instability of the company's project-based revenue recognition.
The sudden appearance and fluctuation of deferred revenue suggest that the company's cash position is heavily reliant on the timing of milestone payments from government contracts. This creates a non-obvious risk where liquidity appears stronger than it is, potentially masking the true operational cash burn.
Quick answers to the most common questions about buying SYRA stock.
As of 2025, Syra Health Corp. Class A Common Stock (SYRA) had total assets of $2.8M including $2.7M in current assets.
Syra Health Corp. Class A Common Stock (SYRA) carries total debt of $0.1M, offset by $1.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Syra Health Corp. Class A Common Stock (SYRA) has total shareholders' equity (book value) of $2.1M ($0.18 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Syra Health Corp. Class A Common Stock (SYRA) reported a current ratio of 4.06x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.